<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37789275</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma.</ArticleTitle><Pagination><StartPage>934</StartPage><MedlinePgn>934</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">934</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-023-11401-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent studies have indicated that epigenetic alterations contribute significantly to lymphoma pathogenesis. A type of epigenetic regulation known as histone acetylation plays a crucial role in transcriptional regulation in eukaryotic cells. Specifically, a significant effect of histone acetylation modifications on the abnormal progression and microenvironment of diffuse large B-cell lymphoma (DLBCL) has been observed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To provide insight into the significance of histone acetylation-related genes, we developed a HAscore model for analyzing histone acetylation patterns in DLBCL samples. Furthermore, KAT2A, a regulator of histone acetylation, was knocked down in DLBCL cell lines to investigate its role in proliferation, cell cycle, and apoptosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The HAscore model has been demonstrated to provide insight into the significance of these patterns, showing that patients with a low HAscore have distinct tumor immune microenvironments and poorer prognoses. Besides, KAT2A was identified as a potential biomarker related to immune infiltration and malignant pathways in DLBCL.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">According to these findings, it is evident that the histone acetylation pattern score model is helpful in describing the immune status of DLBCL and that KAT2A may be used as a biomarker for its treatment.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zhuoya</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Mengfei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yiqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tiange</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaomin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiangxiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. xiangxiangzhou@sdu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 251006, China. xiangxiangzhou@sdu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China. xinw007@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. xinw007@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Branch of National Clinical Research Center for Hematologic Diseases, Jinan, 250021, Shandong, China. xinw007@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 251006, China. xinw007@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No.82170189</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>No.82270200</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>No. 2021T1404223</GrantID><Agency>China Postdoctoral Science Foundation</Agency><Country/></Grant><Grant><GrantID>No.2020ZKMB01</GrantID><Agency>Translational Research Grant of NCRCH</Agency><Country/></Grant><Grant><GrantID>No.2021WWB02</GrantID><Agency>Translational Research Grant of NCRCH</Agency><Country/></Grant><Grant><GrantID>ZR2021YQ51</GrantID><Agency>Natural Science Foundation of Shandong Province</Agency><Country/></Grant><Grant><GrantID>No.2018CXGC1213</GrantID><Agency>Key Technology Research and Development Program of Shandong</Agency><Country/></Grant><Grant><GrantID>No. 2019QL018</GrantID><Agency>Taishan Scholars Program of Shandong Province; Shandong Provincial Engineering Research Center of Lymphoma; Academic Promotion Programme of Shandong First Medical University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="C501179">KAT2A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D051548">Histone Acetyltransferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="Y">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016403" MajorTopicYN="Y">Lymphoma, Large B-Cell, Diffuse</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051548" MajorTopicYN="N">Histone Acetyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DLBCL</Keyword><Keyword MajorTopicYN="N">Histone acetylation</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">KAT2A</Keyword><Keyword MajorTopicYN="N">Tumor microenvironment</Keyword></KeywordList><CoiStatement>The authors have no relevant conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37789275</ArticleId><ArticleId IdType="pmc">PMC10546681</ArticleId><ArticleId IdType="doi">10.1186/s12885-023-11401-4</ArticleId><ArticleId IdType="pii">10.1186/s12885-023-11401-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, et al. Imidazole Ketone Erastin induces ferroptosis and slows Tumor Growth in a mouse lymphoma model. Cell Chem Biol. 2019;26(5):623&#x2013;33e9. doi: 10.1016/j.chembiol.2019.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2019.01.008</ArticleId><ArticleId IdType="pmc">PMC6525071</ArticleId><ArticleId IdType="pubmed">30799221</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartert KT, Wenzl K, Krull JE, Manske M, Sarangi V, Asmann Y, et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia. 2021;35(2):522&#x2013;33. doi: 10.1038/s41375-020-0766-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0766-4</ArticleId><ArticleId IdType="pmc">PMC7483252</ArticleId><ArticleId IdType="pubmed">32139889</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchardt T, Egle A, Greil R. How I treat diffuse large B-cell lymphoma. ESMO Open. 2023;8(1):100750. doi: 10.1016/j.esmoop.2022.100750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esmoop.2022.100750</ArticleId><ArticleId IdType="pmc">PMC9843196</ArticleId><ArticleId IdType="pubmed">36634531</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Reviews Clin Oncol. 2019;16(10):634&#x2013;52. doi: 10.1038/s41571-019-0225-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-019-0225-1</ArticleId><ArticleId IdType="pubmed">31127191</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Li Y, Zhang Y, Fang X, Chen N, Zhou X, et al. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling. J Experimental Clin cancer Research: CR. 2020;39(1):142. doi: 10.1186/s13046-020-01623-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-020-01623-w</ArticleId><ArticleId IdType="pmc">PMC7382040</ArticleId><ArticleId IdType="pubmed">32711549</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604&#x2013;16. doi: 10.1002/ajh.25460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25460</ArticleId><ArticleId IdType="pubmed">30859597</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679&#x2013;90. doi: 10.1038/s41591-018-0016-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0016-8</ArticleId><ArticleId IdType="pmc">PMC6613387</ArticleId><ArticleId IdType="pubmed">29713087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab Vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol. 2020;38(2):155&#x2013;65. doi: 10.1200/JCO.19.00172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.19.00172</ArticleId><ArticleId IdType="pmc">PMC7032881</ArticleId><ArticleId IdType="pubmed">31693429</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45&#x2013;56. doi: 10.1056/NEJMoa1804980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1804980</ArticleId><ArticleId IdType="pubmed">30501490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Chen N, Xu H, Zhou X, Wang J, Fang X, et al. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13(1):77. doi: 10.1186/s13045-020-00906-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-020-00906-1</ArticleId><ArticleId IdType="pmc">PMC7298789</ArticleId><ArticleId IdType="pubmed">32546241</ArticleId></ArticleIdList></Reference><Reference><Citation>Simithy J, Sidoli S, Yuan ZF, Coradin M, Bhanu NV, Marchione DM, et al. Characterization of histone acylations links chromatin modifications with metabolism. Nat Commun. 2017;8(1):1141. doi: 10.1038/s41467-017-01384-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01384-9</ArticleId><ArticleId IdType="pmc">PMC5656686</ArticleId><ArticleId IdType="pubmed">29070843</ArticleId></ArticleIdList></Reference><Reference><Citation>Audia JE, Campbell RM. Histone modifications and Cancer. Cold Spring Harb Perspect Biol. 2016;8(4):a019521. doi: 10.1101/cshperspect.a019521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a019521</ArticleId><ArticleId IdType="pmc">PMC4817802</ArticleId><ArticleId IdType="pubmed">27037415</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez GJ, Richmond PA, Bunker EN, Karman SS, Azofeifa J, Garnett AT, et al. Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res. 2018;46(4):1756&#x2013;76. doi: 10.1093/nar/gkx1225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1225</ArticleId><ArticleId IdType="pmc">PMC5829637</ArticleId><ArticleId IdType="pubmed">29240919</ArticleId></ArticleIdList></Reference><Reference><Citation>Razi S, Haghparast A, Chodari Khameneh S, Ebrahimi Sadrabadi A, Aziziyan F, Bakhtiyari M, et al. The role of tumor microenvironment on cancer stem cell fate in solid tumors. Cell Commun Signal. 2023;21(1):143. doi: 10.1186/s12964-023-01129-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-023-01129-w</ArticleId><ArticleId IdType="pmc">PMC10273768</ArticleId><ArticleId IdType="pubmed">37328876</ArticleId></ArticleIdList></Reference><Reference><Citation>de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374&#x2013;403. doi: 10.1016/j.ccell.2023.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2023.02.016</ArticleId><ArticleId IdType="pubmed">36917948</ArticleId></ArticleIdList></Reference><Reference><Citation>West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Investig. 2014;124(1):30&#x2013;9. doi: 10.1172/JCI69738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI69738</ArticleId><ArticleId IdType="pmc">PMC3871231</ArticleId><ArticleId IdType="pubmed">24382387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Brinton LT, Williams K, Sher S, Orwick SA-O, Tzung-Huei L et al. Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes Acute myeloid leukemia to NAMPT Inhibition. (1557&#x2013;3265 (Electronic)).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054771</ArticleId><ArticleId IdType="pubmed">33542077</ArticleId></ArticleIdList></Reference><Reference><Citation>Verza FA, Das U, Fachin AL, Dimmock JR, Marins M. Roles of histone deacetylases and inhibitors in Anticancer Therapy. 2020;12(6):1664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7352721</ArticleId><ArticleId IdType="pubmed">32585896</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates Immune Surveillance in Lymphoma. Cancer Discov. 2020;10(3):440&#x2013;59. doi: 10.1158/2159-8290.CD-19-0116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-19-0116</ArticleId><ArticleId IdType="pmc">PMC7275250</ArticleId><ArticleId IdType="pubmed">31915197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. 2017;550(7674):128&#x2013;32. doi: 10.1038/nature24028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24028</ArticleId><ArticleId IdType="pmc">PMC6050590</ArticleId><ArticleId IdType="pubmed">28953875</ArticleId></ArticleIdList></Reference><Reference><Citation>Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, et al. Targeting the p300/CBP Axis in Lethal prostate Cancer. Cancer Discov. 2021;11(5):1118&#x2013;37. doi: 10.1158/2159-8290.CD-20-0751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0751</ArticleId><ArticleId IdType="pmc">PMC8102310</ArticleId><ArticleId IdType="pubmed">33431496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai LY, Chen SJ, Xiao SH, Sun QJ, Ding CH, Zheng BN, et al. Targeting p300/CBP attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism. Cancer Res. 2021;81(4):860&#x2013;72. doi: 10.1158/0008-5472.CAN-20-1323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-20-1323</ArticleId><ArticleId IdType="pubmed">33361394</ArticleId></ArticleIdList></Reference><Reference><Citation>Veazey KJ, Cheng D, Lin K, Villarreal OD, Gao G, Perez-Oquendo M, et al. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas. Leukemia. 2020;34(12):3269&#x2013;85. doi: 10.1038/s41375-020-0908-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0908-8</ArticleId><ArticleId IdType="pmc">PMC7688486</ArticleId><ArticleId IdType="pubmed">32576962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Su X, Liu R, Pan Y, Fang J, Cao L, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021;40(10):1836&#x2013;50. doi: 10.1038/s41388-020-01636-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-020-01636-x</ArticleId><ArticleId IdType="pmc">PMC7946638</ArticleId><ArticleId IdType="pubmed">33564072</ArticleId></ArticleIdList></Reference><Reference><Citation>Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu Y-J, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood. 2011;117(10):2910&#x2013;7. doi: 10.1182/blood-2010-08-303701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-08-303701</ArticleId><ArticleId IdType="pmc">PMC3062301</ArticleId><ArticleId IdType="pubmed">21239696</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118&#x2013;27. doi: 10.1093/biostatistics/kxj037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxj037</ArticleId><ArticleId IdType="pubmed">16632515</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Grennan K, Badner J, Zhang D, Gershon E, Jin L, et al. Removing batch effects in analysis of expression microarray data: an evaluation of six batch adjustment methods. PLoS ONE. 2011;6(2):e17238. doi: 10.1371/journal.pone.0017238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017238</ArticleId><ArticleId IdType="pmc">PMC3046121</ArticleId><ArticleId IdType="pubmed">21386892</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Liao W, Luo Q, Yang D, Pan M. Histone Acetylation Regulator-Mediated acetylation patterns define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. 2022;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8821108</ArticleId><ArticleId IdType="pubmed">35145517</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Wang Z, Wu J, Liu M, Li M, Sun Y, et al. Endothelial SIRT6 is vital to prevent hypertension and Associated Cardiorenal Injury through Targeting Nkx3.2-GATA5 signaling. Circul Res. 2019;124(10):1448&#x2013;61. doi: 10.1161/CIRCRESAHA.118.314032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.118.314032</ArticleId><ArticleId IdType="pubmed">30894089</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Tan Y, Zhang C, Zhang Y, Zhang L, Ren P, et al. NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2. EMBO Rep. 2016;17(3):349&#x2013;66. doi: 10.15252/embr.201540505.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201540505</ArticleId><ArticleId IdType="pmc">PMC4772976</ArticleId><ArticleId IdType="pubmed">26882543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572&#x2013;3. doi: 10.1093/bioinformatics/btq170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq170</ArticleId><ArticleId IdType="pmc">PMC2881355</ArticleId><ArticleId IdType="pubmed">20427518</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47&#x2013;e. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27&#x2013;30. doi: 10.1093/nar/28.1.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/28.1.27</ArticleId><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947&#x2013;51. doi: 10.1002/pro.3715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3715</ArticleId><ArticleId IdType="pmc">PMC6798127</ArticleId><ArticleId IdType="pubmed">31441146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587&#x2013;d92. doi: 10.1093/nar/gkac963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac963</ArticleId><ArticleId IdType="pmc">PMC9825424</ArticleId><ArticleId IdType="pubmed">36300620</ArticleId></ArticleIdList></Reference><Reference><Citation>Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype Relationships and Predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248&#x2013;62. doi: 10.1016/j.celrep.2016.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.12.019</ArticleId><ArticleId IdType="pubmed">28052254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast Cancer: understanding the molecular basis of histologic Grade to improve prognosis. JNCI: J Natl Cancer Inst. 2006;98(4):262&#x2013;72. doi: 10.1093/jnci/djj052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djj052</ArticleId><ArticleId IdType="pubmed">16478745</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF&#x3b2; attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544&#x2013;8. doi: 10.1038/nature25501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25501</ArticleId><ArticleId IdType="pmc">PMC6028240</ArticleId><ArticleId IdType="pubmed">29443960</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812&#x2013;30e14. doi: 10.1016/j.immuni.2018.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.03.023</ArticleId><ArticleId IdType="pmc">PMC5982584</ArticleId><ArticleId IdType="pubmed">29628290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie M, Wu Y, Gao M, Li X, Liu C, Ouyang Q, et al. CircMRPS35 suppresses gastric cancer progression via recruiting KAT7 to govern histone modification. Mol Cancer. 2020;19(1):56. doi: 10.1186/s12943-020-01160-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-020-01160-2</ArticleId><ArticleId IdType="pmc">PMC7066857</ArticleId><ArticleId IdType="pubmed">32164722</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Jin X, Ma J, Ding D, Huang Z, Sheng H, et al. HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in Cancer. Cancer Res. 2021;81(6):1486&#x2013;99. doi: 10.1158/0008-5472.CAN-20-2828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-20-2828</ArticleId><ArticleId IdType="pubmed">33419772</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Zhou X, Wang X. Metabolic reprogramming in hematologic malignancies: advances and clinical perspectives. Cancer Res. 2022;82(17):2955&#x2013;63. doi: 10.1158/0008-5472.CAN-22-0917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-22-0917</ArticleId><ArticleId IdType="pmc">PMC9437558</ArticleId><ArticleId IdType="pubmed">35771627</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradella D, Naro C, Sette C, Ghigna C. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer. 2017;16(1):8. doi: 10.1186/s12943-016-0579-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-016-0579-2</ArticleId><ArticleId IdType="pmc">PMC5282733</ArticleId><ArticleId IdType="pubmed">28137272</ArticleId></ArticleIdList></Reference><Reference><Citation>Koushyar S, Powell AG, Vincan E, Phesse TJ. Targeting wnt signaling for the treatment of gastric Cancer. Int J Mol Sci. 2020;21(11).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311964</ArticleId><ArticleId IdType="pubmed">32486243</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontzek F, Staiger AM, Wullenkord R, Grau M, Zapukhlyak M, Kurz KS, et al. Molecular profiling of EBV associated diffuse large B-cell lymphoma. Leukemia. 2023;37(3):670&#x2013;9. doi: 10.1038/s41375-022-01804-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-022-01804-w</ArticleId><ArticleId IdType="pmc">PMC9991915</ArticleId><ArticleId IdType="pubmed">36604606</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhou X, Wang X. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol. 2021;14(1):125. doi: 10.1186/s13045-021-01134-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-021-01134-x</ArticleId><ArticleId IdType="pmc">PMC8369706</ArticleId><ArticleId IdType="pubmed">34404434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennishi D, Hsi ED, Steidl C, Scott DW. Toward a new molecular taxonomy of diffuse large B-cell lymphoma. Cancer Discov. 2020;10(9):1267&#x2013;81. doi: 10.1158/2159-8290.CD-20-0174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0174</ArticleId><ArticleId IdType="pubmed">32616477</ArticleId></ArticleIdList></Reference><Reference><Citation>Leivonen SK, Friman T, Autio M, Vaittinen S, Jensen AW, D&#x2019;Amore F et al. Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas. Haematologica. 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">37259566</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol. 2019;12(1):84. doi: 10.1186/s13045-019-0772-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-019-0772-z</ArticleId><ArticleId IdType="pmc">PMC6704713</ArticleId><ArticleId IdType="pubmed">31438991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Ji YR, Lee YM. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch Pharm Res. 2022;45(6):401&#x2013;16. doi: 10.1007/s12272-022-01389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-022-01389-z</ArticleId><ArticleId IdType="pmc">PMC9250479</ArticleId><ArticleId IdType="pubmed">35759090</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021;28(1&#x2013;2):5&#x2013;17. doi: 10.1038/s41417-020-0183-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-020-0183-x</ArticleId><ArticleId IdType="pmc">PMC7886651</ArticleId><ArticleId IdType="pubmed">32457487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungur CM, Murphy WJ. Positive and negative regulation by NK cells in cancer. Crit Rev Oncog. 2014;19(1&#x2013;2):57&#x2013;66. doi: 10.1615/CritRevOncog.2014010805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevOncog.2014010805</ArticleId><ArticleId IdType="pmc">PMC4242411</ArticleId><ArticleId IdType="pubmed">24941373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Chen W, Lian J, Zhang H, Yu B, Zhang M, et al. The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1&#x3b1;. Cell Death Differ. 2020;27(2):695&#x2013;710. doi: 10.1038/s41418-019-0381-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-019-0381-y</ArticleId><ArticleId IdType="pmc">PMC7206084</ArticleId><ArticleId IdType="pubmed">31320749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D, Song Y, Yu Y, Wang D, Liu B, Chen L, et al. KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer. Cell Death Dis. 2021;12(8):787. doi: 10.1038/s41419-021-04077-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-04077-w</ArticleId><ArticleId IdType="pmc">PMC8357915</ArticleId><ArticleId IdType="pubmed">34381019</ArticleId></ArticleIdList></Reference><Reference><Citation>Haque ME, Jakaria M, Akther M, Cho DY, Kim IS, Choi DK. The GCN5: its biological functions and therapeutic potentials. Clin Sci (Lond) 2021;135(1):231&#x2013;57. doi: 10.1042/CS20200986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20200986</ArticleId><ArticleId IdType="pubmed">33443284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in Acute myeloid leukemia. Cell Rep. 2016;17(4):1193&#x2013;205. doi: 10.1016/j.celrep.2016.09.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.09.079</ArticleId><ArticleId IdType="pmc">PMC5081405</ArticleId><ArticleId IdType="pubmed">27760321</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>